Hmdb loader

HMDBP00484 (UDP-glucuronosyltransferase 1-9) Metabolite Associations

Displaying metabolite protein links 101 - 125 of 166 in total
HMDB ID Name CAS NumberStructureFormula Average Mass
Monoisotopic Mass 		References
HMDB00103626-Hydroxy-5-methoxyindole glucuronide77463-72-0ThumbC15H17NO8339.2974
339.095416525		Not Available
HMDB00103635-Hydroxy-6-methoxyindole glucuronide77463-71-9ThumbC15H17NO8339.2974
339.095416525		Not Available
HMDB001036411-Hydroxyprogesterone 11-glucuronide77710-64-6ThumbC27H38O9506.5852
506.251582814		Not Available
HMDB00103653-alpha-hydroxy-5-alpha-androstane-17-one 3-D-glucuronideThumbC25H38O8466.5644
466.256668192		Not Available
HMDB00116582,8-Dihydroxyquinoline-beta-D-glucuronideThumbC15H15NO8337.2815
337.079766461		Not Available
HMDB0011686p-Cresol glucuronideThumbC13H16O7284.2619
284.089602866		Not Available
HMDB0012226Entacapone130929-57-6ThumbC14H15N3O5305.286
305.101170605		Not Available
HMDB0012302UDP-D-galacturonic acid50722-58-2ThumbC15H22N2O18P2580.2853
580.034284934		Not Available
HMDB0012304UDP-L-iduronateThumbC15H22N2O18P2580.2853
580.034284934		Not Available
HMDB0013847Losartan N2-glucuronideThumbC28H31ClN6O7599.035
598.194275083		Not Available
HMDB00138974-ene-Valproic acidThumbC8H14O2142.1956
142.099379692
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB0013968HydroxyzileutonThumbC11H12N2O3S252.29
252.05686295
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB00140184-HydroxypropofolThumbC12H18O2194.2701
194.13067982
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6. doi: 10.1111/j.1742-7843.2008.00247.x. [PubMed:18816295 ]
HMDB0014440Morphine57-27-2ThumbC17H19NO3285.3377
285.136493479		Not Available
HMDB0014542Sorafenib284461-73-0ThumbC21H16ClF3N4O3464.825
464.08630272
  1. Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13. [PubMed:20706860 ]
  2. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [PubMed:19733976 ]
  3. Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. [PubMed:19228077 ]
HMDB0014551ArdeparinThumbC26H42N2O37S51134.928
1134.006993818		Not Available
HMDB0014645Haloperidol52-86-8ThumbC21H23ClFNO2375.864
375.140134897
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB0014826Mycophenolate mofetil128794-94-5ThumbC23H31NO7433.4947
433.210052351
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
HMDB0014850Flurbiprofen5104-49-4ThumbC15H13FO2244.2609
244.089957865
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB0014869Nateglinide105816-04-4ThumbC19H27NO3317.4226
317.199093735
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB0014900Irinotecan100286-90-6ThumbC33H38N4O6586.678
586.279134968
  1. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501 ]
HMDB0015159Mycophenolic acid24280-93-1ThumbC17H20O6320.3371
320.125988372
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
  2. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
HMDB0015403Lumiracoxib220991-20-8ThumbC15H13ClFNO2293.721
293.061884577
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
HMDB0015573Niflumic Acid4394-00-7ThumbC13H9F3N2O2282.218
282.061612157
  1. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6. [PubMed:16278927 ]
HMDB0029212Quercetin 3-O-glucuronide22688-79-5ThumbC21H18O13478.3598
478.074740662		Not Available
Displaying metabolite protein links 101 - 125 of 166 in total